Amarpreet Sawhney, PhD, President and CEO of Ocular Therapeutix shared his company’s vision: to transform the treatment of eye diseases with sustained release therapeutics. Ocular’s ReSure Sealant, the first and only FDA approved ophthalmic sealant of its kind, is a synthetic, polyethylene glycol hydrogel used to seal corneal incisions following cataract surgery. The company’s most advanced candidate is a Phase III dexamethasone punctum plug for treating post-surgical ocular inflammation and pain.
Amar Sawhney, PhD
Amarpreet Sawhney, Ph.D., co-founded Ocular Therapeautix in 2006, has since served as President and CEO and was elected Chairman of the Board in 2014. Dr. Sawhney served as CEO of Augmenix, from 2008 until 2014 and is a general partner of Incept, LLC, an intellectual property holding company.